John Anthony Lust

Q: What Schools Are Affiliated With John Anthony Lust

John Anthony Lust is affiliated with the following schools: Illinois State University

John Anthony Lust's AcademicInfluence.com Rankings

John Anthony Lust

Philosophy

#8226

World Rank

#11565

Historical Rank

Logic

#5260

World Rank

#6645

Historical Rank

philosophy Degrees

Download Badge

Philosophy

John Anthony Lust's Degrees

Doctorate Medicine Harvard University

Why Is John Anthony Lust Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John Anthony Lust's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Improved survival in multiple myeloma and the impact of novel therapies. (2008) (2142)
Review of 1027 patients with newly diagnosed multiple myeloma. (2003) (2065)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (2013) (1086)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. (2004) (748)
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. (2012) (740)
POEMS syndrome: definitions and long-term outcome. (2003) (695)
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. (1997) (664)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. (2005) (649)
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. (2009) (609)
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. (2002) (535)
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. (1992) (380)
Prognostic value of bone marrow angiogenesis in multiple myeloma. (2000) (378)
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. (2013) (344)
Genomic abnormalities in monoclonal gammopathy of undetermined significance. (2002) (325)
Clinical course of patients with relapsed multiple myeloma. (2004) (321)
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. (2009) (309)
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. (1993) (304)
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. (2004) (303)
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. (2002) (291)
Screening panels for detection of monoclonal gammopathies. (2009) (286)
Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? (1994) (280)
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. (2007) (261)
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. (2009) (241)
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. (2017) (236)
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. (2006) (235)
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. (2010) (229)
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma (2003) (227)
Thalidomide as initial therapy for early-stage myeloma (2003) (224)
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. (2012) (221)
Diagnostic Performance of Quantitative κ and λ Free Light Chain Assays in Clinical Practice (2005) (218)
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. (2004) (215)
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. (2010) (212)
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. (2005) (211)
Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis (2007) (206)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy (2007) (199)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) (2010) (193)
Long-term survival (10 years or more) in 30 patients with primary amyloidosis. (1999) (187)
Thalidomide in the treatment of relapsed multiple myeloma. (2000) (187)
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. (2007) (186)
Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. (1994) (185)
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. (2008) (185)
Monoclonal gammopathies and associated skin disorders. (1999) (184)
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma (2013) (182)
Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. (2006) (181)
Thalidomide for previously untreated indolent or smoldering multiple myeloma (2001) (180)
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. (2013) (171)
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. (2011) (167)
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. (2011) (164)
Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil (2000) (157)
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. (2007) (155)
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells (2007) (150)
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. (2001) (148)
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria (2018) (145)
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. (2013) (143)
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. (2009) (141)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis (2003) (139)
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. (2012) (138)
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. (2003) (133)
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. (2005) (127)
Prognostic model for disease‐specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia (2006) (126)
Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugs (2010) (123)
Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. (2003) (122)
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. (2012) (117)
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. (2010) (116)
Heterogeneity of natural killer cells in the mouse (1981) (110)
Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma (1993) (109)
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. (2014) (107)
Therapy for Relapsed Multiple Myeloma: GUIDELINES FROM THE MAYO STRATIFICATION FOR MYELOMA AND RISK‐ADAPTED THERAPY (2017) (107)
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. (1996) (107)
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. (2009) (106)
T-cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. (1991) (104)
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. (2005) (104)
Prognostic value of angiogenesis in solitary bone plasmacytoma. (2003) (101)
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016 (2017) (101)
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. (2015) (100)
Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) Is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM). (2009) (95)
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma (2004) (95)
Primary follicular mucinosis: long-term follow-up of patients younger than 40 years with and without clonal T-cell receptor gene rearrangement. (2002) (95)
Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques. (2004) (93)
Clinical implication of centrosome amplification in plasma cell neoplasm. (2006) (92)
Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. (1995) (91)
Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma (2014) (89)
Monoclonal gammopathies of undetermined significance. (1989) (88)
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category (2017) (88)
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy (2004) (87)
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis (2009) (87)
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma (2013) (85)
THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA (1999) (77)
Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. (1999) (75)
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement (2018) (75)
Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. (1999) (75)
Smoldering multiple myeloma requiring treatment: time for a new definition? (2013) (74)
Outcomes of patients with renal monoclonal immunoglobulin deposition disease (2016) (74)
Outcomes of patients with POEMS syndrome treated initially with radiation. (2012) (71)
Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy (2004) (70)
Trends and outcomes of modern staging of solitary plasmacytoma of bone (2012) (70)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. (2014) (70)
Flow Cytometric Assessment of TCR-Vβ Expression in the Evaluation of Peripheral Blood Involvement by T-Cell Lymphoproliferative Disorders (2004) (68)
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents (2016) (67)
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience (2015) (66)
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis (2015) (66)
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial (2011) (65)
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. (2003) (65)
Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma (2016) (64)
Effect of complete response on outcome following autologous stem cell transplantation for myeloma (2000) (63)
Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. (2007) (63)
Autologous stem cell transplantation for relapsed and primary refractory myeloma (1999) (62)
Natural history of t(11;14) multiple myeloma (2017) (62)
Bone marrow angiogenesis in multiple myeloma: effect of therapy (2002) (62)
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression (2017) (61)
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis (2014) (60)
Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia (2017) (59)
A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing (2019) (59)
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. (2011) (58)
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma (2004) (58)
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death (2015) (57)
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma (2017) (56)
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria (2018) (56)
Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. (1994) (55)
Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma (1999) (54)
Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. (2002) (54)
Long‐term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience (2016) (54)
N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma (2016) (54)
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma (2012) (54)
Expression of CD52 on plasma cells in plasma cell proliferative disorders. (2003) (53)
Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma (2018) (53)
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. (2008) (53)
Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma (2010) (53)
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma (2016) (51)
Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1β and NO lead to inactivation of caspases (2006) (50)
Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis (1999) (49)
Role of cytokines in multiple myeloma. (1999) (49)
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma (2005) (48)
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? (2013) (48)
A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. (2001) (48)
Genetic expression of endothelial nitric oxide synthase in human atrial myocardium. (1996) (47)
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. (2017) (47)
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study (2020) (45)
Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival. (2006) (44)
Phase II trial of high‐dose dexamethasone for previously treated immunoglobulin light‐chain amyloidosis (1999) (44)
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature (2010) (43)
Induction therapy pre‐autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation (2016) (43)
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis (2018) (43)
Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. (2016) (43)
Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. (2006) (42)
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients (2012) (42)
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. (2020) (41)
A phase II trial of imatinib in patients with refractory/relapsed myeloma (2006) (41)
Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma (2018) (41)
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response (2020) (41)
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains (2018) (41)
The role of interleukin-1 beta in the pathogenesis of multiple myeloma. (1999) (41)
Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia. (2003) (40)
Myelomatous Involvement of the Central Nervous System. (2016) (38)
Correlates of Pay and Benefit Satisfaction: The Unique Case of Public University Faculty (1992) (38)
Plasma levels of tumour necrosis factor alpha and interleukin‐6 predict progression‐free survival following thalidomide therapy in patients with previously untreated multiple myeloma (2003) (38)
Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma (1998) (37)
Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition (2017) (37)
Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation (2016) (37)
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma (1999) (37)
The pleiotypic response in mammalian cells: search for an intracellular mediator. (1972) (36)
Intestinal Lymphangiectasia With Protein-Losing Enteropathy in Waldenstrom Macroglobulinemia (2007) (35)
Impact of acquired del(17p) in multiple myeloma. (2019) (35)
Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio (2018) (34)
Scleromyxedema: a complete response to prednisone. (1999) (34)
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival (2017) (33)
Ten‐year survivors in AL amyloidosis: characteristics and treatment pattern (2019) (32)
Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy (2014) (32)
Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light‐chain amyloidosis (2016) (32)
Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes. (1995) (32)
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma (2013) (32)
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma (2017) (30)
Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents (2012) (30)
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma (2015) (30)
Thalidomide plus dexamethasone (thal/dex) and thalidomide alone (thal) as first line therapy for newly diagnosed myeloma (mm) (2000) (30)
Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. (2000) (29)
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome (2017) (29)
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. (2005) (28)
Short communication: Absence of evidence of HTLV-3 and HTLV-4 in patients with large granular lymphocyte (LGL) leukemia. (2008) (28)
Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. (2015) (28)
Impact of dexamethasone responsiveness on long-term outcome in patients with newly diagnosed myeloma. (2009) (28)
T‐cell non‐hodgkin lymphoma in human immunodeficiency virus‐1‐infected individuals (1989) (28)
Long‐term results of single‐agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma (2010) (28)
Recensie: The Psalms. Strophic Structure and Theological Commentary (Eerdmans Critical Commentary) / Samuel Terrien (Grand Rapids MI, 2003) (2003) (28)
Clinical characteristics and outcomes in biclonal gammopathies (2016) (27)
Unusual presentation of extranodal peripheral T‐cell lymphomas with multiple paraneoplastic features (1991) (27)
Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-κB activity and tumor growth in murine models of multiple myeloma. (2012) (27)
Enhancing the R‐ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells (2019) (27)
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance (2018) (26)
Natural history of multiple myeloma with de novo del(17p) (2019) (26)
Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials (2017) (26)
T-cell large granular lymphocytic leukemia and pure red cell aplasia in a patient with type I autoimmune polyendocrinopathy: response to immunosuppressive therapy. (1994) (25)
Recensie: Hittite Diplomatic Texts. second edition (SBL Writings from the Ancient World Series, 7) / G. Beckman (Atlanta, GA, 1999) (2000) (25)
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis (2020) (25)
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment (2016) (25)
IL-1β expression in IgM monoclonal gammopathy and its relationship to multiple myeloma (2002) (25)
Molecular genetics and lymphoproliferative disorders (1996) (25)
Natural history of thromboembolism in AL amyloidosis (2006) (25)
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis (2019) (24)
Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R). (1995) (24)
Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. (2006) (24)
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis (2020) (24)
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. (2016) (23)
Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma (2008) (23)
Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis (2017) (23)
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. (2017) (22)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma (2008) (22)
Human Resource Champions: The Next Agenda for Adding Value and Delivering Results (1998) (22)
Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM). (2004) (22)
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia (2017) (21)
Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. (2011) (21)
Role of cytokines in the pathogenesis of monoclonal gammopathies. (1994) (21)
Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis (2008) (20)
Localized Tongue Amyloidosis (2013) (20)
Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia (2000) (19)
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients (2021) (19)
Marrow hypoplasia associated with a monoclonal CD8 large granular lymphocyte proliferation: reversal with cyclophosphamide and prednisone. (1989) (19)
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation (2017) (18)
Comparative analysis of staging systems in AL amyloidosis (2018) (18)
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma (2018) (18)
Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis (2020) (18)
Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma (2015) (17)
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. (2021) (17)
Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM). (2006) (17)
A conceptual model of the determinants of employee benefit satisfaction (1992) (17)
HTLV-II infection is rare in patients with large granular lymphocyte leukemia. (1994) (16)
The monoclonal gammopathies (paraproteins). (1990) (16)
Immunoglobulin D amyloidosis: a distinct entity. (2012) (16)
Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis (2019) (16)
Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma (2020) (16)
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy (2016) (16)
Hematology patient reported symptom screen to assess quality of life for AL amyloidosis (2017) (16)
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma (2018) (16)
A phase ii trial of thalidomide in the treatment of relapsed multiple myeloma (mm) with laboratory correlative studies (2000) (16)
A novel report of cig‐FISH and cytogenetics in POEMS syndrome (2008) (16)
Evaluation of capillary electrophoresis in polymer solutions with laser‐induced fluorescence detection for the automated detection of T‐cell gene rearrangements in lymphoproliferative disorders (1996) (16)
Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis (2017) (16)
Product Owner Manuals: An Exploratory Study of Nonreaders Versus Readers1 (1992) (15)
Specificity of serum and urine protein electrophoresis for the diagnosis of monoclonal gammopathies. (2010) (15)
Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. (2018) (15)
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio (2020) (15)
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials (2019) (14)
Time to plateau as a predictor of survival in newly diagnosed multiple myeloma (2018) (14)
Analysis of low natural killer cell activity in 89Sr‐treated mice (1982) (14)
Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma. (2007) (13)
Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial (2018) (13)
A Note on Issues Concerning the Measurement of Self‐Efficacy1 (1993) (13)
Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest? (1995) (13)
Low Dose Single Agent Thalidomide Is Tolerated in Patients with Primary Systemic Amyloidosis, but Responses Are Limited. (2004) (12)
Models of satisfaction with benefits: Research implications based on the nature of the construct (1990) (12)
Perceptions of Desirable Organizational Reforms in Chinese State Enterprises (1990) (12)
Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years, (2011) (12)
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. (2020) (12)
Incidence and Survival Outcomes Of Extramedullary Myeloma (2013) (12)
Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL) (2018) (12)
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type (2016) (11)
Cardiac Biomarkers Predict for Ability To Tolerate and Complete Therapy with Lenalidomide ± Dexamathosone in AL Amyloidosis. (2006) (11)
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma (2018) (11)
Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia (2020) (11)
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. (2021) (10)
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma (2020) (10)
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi‐parametric flow cytometry method (2019) (10)
Substratification of patients with newly diagnosed standard‐risk multiple myeloma (2019) (10)
In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO) (2015) (10)
Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score (2010) (10)
Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease (2019) (10)
Utility of serum free light chain ratio in response definition in patients with multiple myeloma. (2020) (10)
The use of product owner manuals: A comparison of older versus younger consumers (1992) (9)
Superior Survival in Primary Systemic Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Transplant : A Case Control Study Running Head: Survival in AL, Case Control Study (2004) (9)
Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma (2010) (9)
Gamma delta T lymphocytosis associated with common variable immunodeficiency. (1997) (9)
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients (2020) (9)
How aware are employees of their benefits? Findings from two companies. (1996) (9)
Long Term Follow-up of Patients with Immunoglobulin Light Chain Amyloidosis Treated with Lenalidomide and Dexamethasone. (2008) (8)
γδ T Lymphocytosis Associated with Common Variable Immunodeficiency1 (2004) (8)
Thalidomide and dexamethasone in newly diagnosed multiple myeloma: Long-term results in patients not undergoing upfront autologous stem cell transplantation (2005) (8)
Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma (2019) (8)
Cytogenetic analysis using multiple myeloma targets in POEMS syndrome (2007) (8)
Dendritic cell-based idiotype vaccination for primary systemic amyloidosis (2000) (7)
Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria (2019) (7)
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy (2019) (7)
A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients. (2009) (7)
Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination. (2005) (6)
Immunoglobulins and Laboratory Recognition of Monoclonal Proteins (2013) (6)
Recensie: Hittite Myths (SBL Writings from the Ancient World Series, 2) / Harry E. Hoffner (Atlanta, GA, 1998) (2000) (6)
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival (2016) (6)
Career Movement of Female Employees Holding Lower-Level Positions: An Analysis of the Impact of the Type A Behavior Pattern (1999) (6)
Prognostic Significance of Circulating Plasma Cells by Multi-Parametric Flow Cytometry in Light Chain Amyloidosis (2018) (6)
Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma (2017) (6)
Myelomatous Involvement of the Central Nervous System: Mayo Clinic Experience (2013) (6)
Recensie: Reconsidering Israel and Judah. Recent Studies in Deuteronomistic History (Sources for Biblical and Theological Study, 8) / Gary N. Knoppers & J. Gordon McConville (ed.) (Winona Lake IN, 2000) (2001) (6)
Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience (2015) (6)
The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? (2019) (6)
Benefits management and communication: A marketing orientation (1994) (6)
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. (2021) (6)
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients (2021) (6)
Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response (2018) (6)
A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma (2013) (6)
Analysis of Outcome after Autologous Stem Transplantation in Patients with Newly Diagnosed Myeloma: Comparison of Different Induction Regimens. (2006) (5)
In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders. (2005) (5)
An investigation of the relationship between self-efficacy and the communication effectiveness of product manual formats (1995) (5)
A Test of a Model of Consumers' Responses to Product Manual Safety Information1 (1998) (5)
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort (2021) (5)
Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM) (2020) (5)
Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort (2011) (5)
Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. (2021) (5)
Characterization and prognostic implication of delayed complete response in AL amyloidosis (2020) (4)
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. (2020) (4)
Prognostic restaging after treatment initiation in patients with AL amyloidosis. (2020) (4)
Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma (2009) (4)
Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. (2021) (4)
Serum free light chain measurements to reduce 24‐h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein (2018) (4)
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. (2018) (4)
Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant (2015) (4)
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis (2018) (4)
Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome (2008) (4)
Recensie: Reading and Hearing the Book of the Twelve (SBL Symposium Series, 15) / James D. Nogalski & Marvin A. Sweeney (ed.) (Atlanta GA, 2000) (2001) (4)
Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis (2016) (4)
Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function (2010) (4)
Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma (2020) (4)
Lack of correlation between mycoplasma induced IFN-gamma production in vitro and natural killer cell activity against FLD-3 cells. (1983) (4)
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma. (2009) (4)
17p Deleted Multiple Myeloma: Clinical Outcomes and Predictive Factors For Acquisition Of 17p Deletion (2013) (4)
United States Versus Mexican Perceptions of The Impact of the North American Free Trade Agreement (1994) (4)
Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis. (2005) (4)
Solitary Plasmacytoma of Bone and Extramedullary Plasmacytoma (2004) (4)
Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma (2012) (3)
Recensie: Josephus' story of the later monarchy (AJ 9,1 - 10,185) (BETL, 145) / C. Begg (Leuven, 2000) (2000) (3)
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma (2019) (3)
A Phase II Trial of Gleevec™ in Patients with Refractory/Relapsed Myeloma. (2004) (3)
Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM) (2016) (3)
Mexican and U.S. attitudes toward the nafta (1994) (3)
Clinical Outcome of Immunoglobulin Light Chain Amyloidosis Affecting the Kidney (2008) (3)
Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM). (2016) (3)
Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (2011) (3)
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma (2017) (3)
The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? (2020) (3)
Improving Survival in Multiple Myeloma: Impact of Novel Therapies. (2007) (3)
TCL-461: Clinical Activity of Systemic VSV-IFNβ-NIS Oncolytic Virotherapy in Patients with Relapsed Refractory Hematologic Malignancies (2021) (2)
Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage (2016) (2)
A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289) (2010) (2)
Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia (2016) (2)
Interplay Between IL-1, IL-6 and IL-17 in IL-1 Receptor Antagonist (IL-1Ra) Treated Multiple Myeloma Patients (2012) (2)
Cytokine involvement in the prediction and prevention of MGUS to multiple myeloma. (2006) (2)
Implications and outcomes of MRD‐negative multiple myeloma patients with immunofixation positivity (2019) (2)
Use of the Serum Free Light Chain Assay in Assessment of Response to Therapy in Multiple Myeloma: Validation of Recently Proposed Response Criteria in a Prospective Clinical Trial of Lenalidomide Plus Dexamethasone for Newly Diagnosed Multiple Myeloma. (2005) (2)
Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma. (2009) (2)
Preclinical Studies Using Polyethylenimine (PEI) Nanoparticles Complexed with Eukaryotic Translation Initiation Factor 5A (eIF5A) siRNA and eIF5AK50R Plasmid DNA Demonstrates Significant Anti-Myeloma Activity in Vitro and in Vivo (2008) (2)
Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison. (2006) (2)
A Test of a Model of Consumers' Responses to Product-Manual Safety Information: A Replication and Extension1 (2001) (2)
Recensie: The Idea of Retribution in the Book of Ezekiel (VTSuppl., 129) / Ka Leung Wong (Leiden, 2001) (2001) (2)
Survival Outcomes Of Very Young (<40 years) Myeloma Patients (2013) (2)
Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM) (2020) (2)
Recensie: The Book of Ezekiel. Theological and Anthropological Perspectives (SBL Symposium Series, 9) / Margaret S. Odell & John Strong (ed.) (Atlanta G, 2000) (2001) (2)
Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents (2013) (2)
The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma (2020) (2)
Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010. (2014) (2)
Periodic fever syndrome with relapsing glomerulonephritis: a case report and teaching points (2011) (2)
Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis (2020) (2)
Long‐term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy (2014) (2)
Composite Organ and Hematologic Response Model Risk Stratifies Patients with Light Chain Amyloidosis (2017) (2)
Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome. (2019) (2)
Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis (2017) (2)
Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma (2020) (2)
Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma (2018) (2)
Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis. (2012) (2)
Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC). (2019) (2)
MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients (2020) (2)
Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL) (2018) (2)
Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant (2012) (2)
Therapeutic Strategies For Initial Treatment Of AL Amyloidosis: Implications Of Therapy and Response On Outcome (2013) (2)
A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome (2019) (2)
Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies. (2014) (2)
MYOCARDIAL CONTRACTION FRACTION, A NEW ECHOCARDIOGRAPHIC PARAMETER FOR PREDICTION OF SURVIVAL IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS (2016) (1)
Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma. (2009) (1)
Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes (2015) (1)
Recensie: The Dictionary of Classical Hebrew. Volume V / David J.A. Clines (ed.) (Sheffield, 2001) (2003) (1)
Gamma/Delta T Cell Lymphomas Involving The Skin: Report of a New Patient With Subcutaneous Lesions And Review of the Literature.: 26 (1997) (1)
Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition. (2017) (1)
The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis (2011) (1)
Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy. (2020) (1)
Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis (2016) (1)
Recensie: Minor Prophets. Part 2 (FOTL, 22) / Michael H. Floyd (Grand Rapids MI, 2000) (2000) (1)
Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial. (2011) (1)
Depth of Organ Response in Newly Diagnosed AL Amyloidosis Is Associated with Improved Survival: Improved Outcome Discrimination with Graded Organ Response (2017) (1)
Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment (2020) (1)
Differential Cytokine and Chemokine Profiles from MGUS, SMM, and MM Patient Bone Marrow; Significance of Stromal Interaction and Correlation of IL-8 with the Progression of Myeloma. (2004) (1)
MALDI-TOF Mass Spectrometry Can Distinguish Immunofixation Bands of the Same Isotype as Monoclonal or Biclonal Proteins. (2021) (1)
Elimination of the Need for Urine Studies during Diagnostic Studies of Monoclonal Gammopathies by the Combined Use of Serum Immunofixation and Serum Free Light Chain Assays. (2006) (1)
Monoclonal gammopathies of undetermined significance: the transition from MGUS to myeloma (2004) (1)
Disparities in Outcomes of Patients with Multiple Myeloma Based on Geographic Distance from NCI-Designated Cancer Centers: A SEER Based Analysis (2017) (1)
ABT-737, an Inhibitor of Bcl-2/Bcl-XL Proteins, Is Cytotoxic in Multiple Myeloma Cells. (2005) (1)
The impact of alternate information sources on compensation satisfaction (1990) (1)
Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy (2018) (1)
Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients (2020) (1)
Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma. (2012) (1)
SUPPRESSOR CELLS ACTIVE AGAINST NK-B BUT NOT NK-A CELLS IN MICE TREATED WITH RADIOACTIVE STRONTIUM (1982) (1)
Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis (2016) (1)
776-4 Intact cNOS-NO-cGMP Pathway in the Failing Human Heart (1995) (1)
Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis (2020) (1)
A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH (2019) (1)
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses (2014) (1)
Retrospective Study of the Efficacy of Bortezomib in Primary Systemic Amyloidosis. (2009) (1)
Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma—a Single Center Experience (2017) (1)
Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression. (2016) (1)
Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies (2014) (1)
Eligibility f or H ematopoietic S tem-Cell T ransplantation for P rimary S ystemic A myloidosis I s a F avorable Prognostic F actor f or S urvival (2001) (1)
Systemic AL Amyloidosis Myopathy: Presentation, Diagnostic Pitfalls and Outcome (2016) (1)
Recensie: Psalms. 101-150 (WBC, 21) / Leslie J. Allen (Nashville TN, 2002) (2003) (1)
Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies (2011) (1)
Recensie: Prophecy in Its Ancient Near Easertn Context (SBL Symposium Series, 13) / Matti Nissinen (ed.) (Atlanta, 2000) (2001) (1)
Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma (2013) (1)
Factors predicting organ response in light chain amyloidosis (AL). (2017) (1)
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma (2019) (1)
Recensie: Helsinki Perspectives on the Translation Technique of the Septuagint (Publ. of the Finnish Exeg. Soc., 82) / Raja Sollamo & Seppo Sipilä (ed.) (Helsinki, 2001) (2002) (1)
Analysis of serum immunoglobulin free light chains in primary systemic amyloidosis and light chain deposition disease by nephelometry (2001) (1)
The use of realistic job previews in the provision of health hazard information (1989) (1)
Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis. (2007) (1)
Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma. (2013) (1)
What Does AL Amyloidosis Look like in the Era of Mass Spectrometry Typing (2017) (1)
A481 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma (2009) (1)
Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis (2019) (1)
Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma (2018) (1)
Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma. (2004) (1)
Does stage migration exist in active multiple myeloma (MM) (2012) (1)
Recensie: Dynamics of Diselection. Ambiguity in Genesis 12-36 (SBL Semeia Studies) / Heard, R. Christoph (Atlanta AG, 2001) (2003) (1)
Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy (2019) (1)
Early Paraprotein Kinetics and Response to Treatment in Multiple Myeloma (2017) (1)
14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH). (2007) (1)
Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma. (2006) (1)
Smoldering Multiple Myeloma (2010) (1)
Friend virus induced erythroleukemia cells (fld-3): rejection by irradiated mice and lysis by natural killer cells. Abstr. (1980) (1)
Recensie: Writings and Speech in Israelite and Ancient Near Eastern Prophecy (SBL Symposium Series, 10) / Ehud Ben Zvi & Michael H. Floyd (ed.) (Atlanta G, 2000) (2001) (1)
Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM). (2016) (1)
Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component (2011) (1)
Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type (2017) (1)
A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders (2020) (0)
A simple model to predict survival using age, comorbidities and functional status in patients with multiple myeloma (MM) (2015) (0)
Survival in Primary SyStemic amyloidoSiS (2010) (0)
Recensie: Persia and Torah (SBL Symposium Series, 17) / James W. Watts (Atlanta GA, 2001) (2002) (0)
Definition of a high-risk population among patients with AL amyloidosis not undergoing autologous stem cell transplantation using bone marrow plasmacytosis and the presence of CRAB. (2013) (0)
Recensie: X Congress of the International Organisation for Septuagint and Cognate Studies, Oslo 0998 (SBL SCS Series, 51) / Bernard A. Taylor (Atlanta GA, 2001) (2001) (0)
Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL) (2018) (0)
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. (2019) (0)
Prognostic Value of Bone Marrow Angiogenesis in Newly Diagnosed Multiple Myeloma: A Comparison with Conventional Prognostic Factors. (2005) (0)
Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category (2016) (0)
Recensie: The Dead Sea Scrolls at Fifty (SBL Early Judaism and Its Literature, 15) / Robert A. Kugler & Eileen M. Schuller (ed.) (Atlanta GA, 1999) (2000) (0)
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria (2018) (0)
Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma. (2012) (0)
Comparison of Myeloma Cell Gene Expression Profiles Pre and Post Thalidomide - Dexamethasone Therapy Provides Insight into Potential Mechanisms. (2005) (0)
Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma (2018) (0)
The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma. (2017) (0)
IgD Amyloidosis: An Unrecognized Entity (2011) (0)
Stromal Cell IL-8 Production Is Increased in MM and May Impact Both Tumor Cells and the Microenvironment. (2005) (0)
Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma. (2018) (0)
Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment. (2015) (0)
light-chain amyloidosis: long-term results from a phase 2 trial Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for (2012) (0)
Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL) (2018) (0)
Recensie: Micah (The Forms of the OT Literature, 21B) / Ehud Ben Zvi (Grand Rapids MI, 2000) (2000) (0)
A366 Relevance of Conventional Prognostic Factors in Multiple Myeloma (MM) in the Era of Novel Therapies (2009) (0)
Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light chain amyloidosis (2008) (0)
Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience. (2004) (0)
The use of proteasome inhibitors among patients with POEMS syndrome. (2017) (0)
Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma. (2016) (0)
Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14) (2019) (0)
Amy L. Kristof-Brown and Jon Billsberry (Eds.). Organizational Fit: Key Issues and New Directions. Malden, MA: John Wiley & Sons, Ltd., 2013, 246 pages, $127.95 hardcover. (2015) (0)
Recensie: Unless Some One Guide Me. FS K.A. Deurloo (Amsterdamse Cahiers. Supplement Series, 2) / R. Zuurmond & Others (Maastricht, 2000) (2002) (0)
Prognostic Significance of Baseline High Risk Features during Follow-up in Immunoglobulin Light Chain Amyloidosis (2017) (0)
Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma. (2016) (0)
Reduction In Proliferative Rate of Myeloma Plasma Cells Measured by the Plasma Cell Labeling Index Predicts Improved Survival In Multiple Myeloma (2010) (0)
Natural Killer Cells Subsets (1982) (0)
IgH translocations are common in patients with primary systemic amyloidosis (al) (2000) (0)
Implications of rapidity of response to initial therapy in multiple myeloma. (2013) (0)
ITF2357, a Novel Histone Deacetylase Inhibitor, Demonstrates Significant Apoptotic Activity Against Human Multiple Myeloma Cells. (2007) (0)
Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients (2014) (0)
Prospective R andomized T rial o f M elphalan a nd P rednisone Versus V incristine, C armustine, M elphalan, Cyclophosphamide, a nd P rednisone i n t he T reatment of P rimary S ystemic A myloidosis (1999) (0)
Characterization of Long-Term Multiple Myeloma Survivors (2018) (0)
Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes. (2016) (0)
IL-1 Antagonists Are More Effective at Inhibiting IL-6 Production Than Apoptosis Inducing Agents: Implications for Targeting the Myeloma Proliferative Component. (2009) (0)
Recensie: Invitation to the Apocrypha / Daniel Harrington (Grand Rapids, MI, 1999) (2000) (0)
The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma (2016) (0)
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome (2018) (0)
PLASMA CELL LABELING INDEX, BETA 2-MICROGLOBULIN, AND C-REACTIVE PROTEIN :WHATH IS THE BEST COMBINATION FOR MYELOME PROGNOSIS ? AUTHORS' RESPONSE (1993) (0)
Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma (2018) (0)
Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels. (2020) (0)
Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population (2018) (0)
Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis (2020) (0)
Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1β and NO lead to inactivation of caspases (2006) (0)
Beneficial effect of complete response and type of therapy in multiple myeloma. (2013) (0)
Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden (2016) (0)
Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents. (2006) (0)
Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL). (2017) (0)
Correction to: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis (Leukemia, (2020), 34, 4, (1135-1143), 10.1038/s41375-019-0655-x) (2020) (0)
299 POSTER Therapeutic intervention in a murine model of multiple myeloma with PEI nanocomplexes bearing an eIF5A siRNA and eIF5AK50R pDNA resulted in a significant anti-tumoural response (2008) (0)
Abstract A196: Characterization of stability and biological activity of the cancer gene therapy biologic SNS01 following storage at ambient and freezing temperatures (2009) (0)
Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma (2018) (0)
A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM) (2020) (0)
Impact of Acquired Del(17p) in Patients with Multiple Myeloma (2018) (0)
Natural killer (nk) cell lysis of friend erythroleukemia cells (fld-3) does not require interferon (ifn) induction. Abstr. (1981) (0)
Human gastrin (GAS) RFLP recognised by digestion with BamHI or EcoRI. (1987) (0)
survival in 302 patients with newly diagnosed multiple myeloma Circulating plasma cells detected by flow cytometry as a predictor of (2013) (0)
Recensie: Intolerant Monolmatry in the Deuteronomistic History (Publ. of the Finnish Exeg. Society, 76) / Juha Pakkala (Helsinki, 1999) (2001) (0)
CD38, a myeloma cell marker Oncolytic measles viruses displaying a single chain antibody against (2013) (0)
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. (2012) (0)
Autologous Stem Cell Transplantation Provides Additional Cytoreduction Following Induction Therapy in Multiple Myeloma. (2006) (0)
N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM) (2015) (0)
Patient-Reported Outcome Driven Case Management System for Hematology — a Prospective Study (2018) (0)
Timing of Stem Cell Transplantation and Outcomes in Light Chain Amyloidosis (2016) (0)
Absolute Values of Serum Immunoglobulin Free Light Chains Predict for Survival in Patients with Primary Systemic Amyloidosis Undergoing Peripheral Blood Stem Cell Transplant. (2005) (0)
The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL Amyloidosis (2011) (0)
Comparison of Newly Diagnosed and Relapsed Refractory Multiple Myeloma Using Transcriptional Profiling of Myeloma Cells. (2005) (0)
Applied Research as an Experiential Learning Tool in the Foreign International Management Classroom (1993) (0)
Identification of Genes Associated with Increased Bone Marrow Angiogenesis in Multiple Myeloma. (2005) (0)
Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma (2018) (0)
Recensie: Psalm 119 (Biblical and Judaic Studies from the Univ. of Calif., 6) / David Noel Freedman (Winnona Lake, IN, 1999) (2000) (0)
Recensie: The Psalms. Translated by Albert Pietersma (NETS) / Albert Pietersma (Oxford & New York, 2000) (2001) (0)
Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis (2016) (0)
Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma (2016) (0)
Recensie: Yahwism after the Exile (Studies in Theology and Religion, 5) / Albertz, R. & Becking, B. (ed.) (Asszn, 2003) (2003) (0)
Abstract 2449: A novel humanized anti-IL-1beta antibody is highly effective at inhibiting IL-1 induced IL-6 production in myeloma patients in vitro (2010) (0)
Brief report Efﬁcacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma (2011) (0)
Functional P2X7 Receptors in Myeloma Cell Lines and Myeloma Patient Bone Marrow Samples Can Be Blocked by Specific P2X7 Receptor Antagonists: Implications for Myeloma Therapy and Chemotherapy Induced Inflammation. (2011) (0)
Recensie: Isaiah. Part 2. Volume 2. Chapters 28-39 (Historical Commentary on the OT) / W. A. M. Beuken (Leuven, 2000) (2000) (0)
Recensie: I Esdras. A Textcritical Commentary: The Story of the Three Youths (SBL SCS Series, 50) / Zipora Talshir (Atlanta GA, 2001) (2002) (0)
Combination T herapy W ith T halidomide P lus D examethasone for N ewly D iagnosed M yeloma (2002) (0)
Induction of Vascular Endothelial Growth Factor (VEGF) and Interleukin 6 (IL-6) in Stromal Cells by Plasma Cells from Different Stages of Myeloma. (2006) (0)
Prevention of active multiple myeloma (MM) using IL-1 receptor antagonist (IL-1ra) and low-dose dexamethasone (Dex) and monitoring the high sensitivity C-reactive protein (hsCRP) (2007) (0)
Pilot study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with POEMS Syndrome (2019) (0)
The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients (2015) (0)
Multi-Parameter Flow Cytometry(FC) Can Detect Proliferating Myeloma Cells After Treatment: Implications for Targeting the Myeloma Proliferative Component (2010) (0)
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma (2018) (0)
amyloidosis Activity of pomalidomide in patients with immunoglobulin light-chain (2012) (0)
Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis (2018) (0)
Recensie: The Twelve Prophets. Volume 1 (Berit Olam) / Marvin H. Sweeney (Collegevill MN, 2000) (2001) (0)
Recensie: Thematic Threads in the Book of the Twelve (BZAW, 325) / P.L. Redditt & A. Schart (Berlin, 2003) (2003) (0)
Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma (2019) (0)
Recensie: The Survivors of Israel. the Theology of Pre-Christian Judaism / Mark Adam Elliott (Cambrige, 2000) (2001) (0)
Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma (2020) (0)
Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy (2016) (0)
Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL). (2017) (0)
IL-1-6 Blocking IL-1 beta to prevent progression to multiple myeloma (2010) (0)
Recensie: The Pentateuch in the Twentieth Century / Ernest W. Nicholson (Oxford, 1998) (2001) (0)
A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma (2012) (0)
Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma (2019) (0)
Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation (2016) (0)
Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma (2020) (0)
Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL). (2015) (0)
Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis (2016) (0)
Systemic Delivery of the Cancer Gene Therapy Biologic, SNS01, Has Significant Anti-Tumoral Activity in a Murine Model of Multiple Myeloma. (2009) (0)
Recensie: The Roots of Rabbinic Judaism. An Intellectual History from Ezekiel to Daniel / Gabriele Boccaccini (Grand Rapids MI, 2002) (2002) (0)
diagnosis and follow-up of patients with POEMS syndrome The utility of plasma vascular endothelial growth factor levels in the (2013) (0)
Natural history of multiple myeloma with de novo del(17p) (2019) (0)
Natural history of delp53 multiple myeloma. (2018) (0)
Recensie: Treasures of Wisdom. FS M. Gilbert (BETL, 143) / N Calduch-Benages & J. Vermeylen (ed.) (Leuven, 1999) (2001) (0)
Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients (2021) (0)
Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma (2013) (0)
Abstract 655: Hyperdiploidy in plasma cell disorders using multi-parametric flow cytometry (MFC) vs. FISH (2018) (0)
Predictors of Early Treatment Failure following initial therapy for Systemic Immunoglobulin Light Chain Amyloidosis (2017) (0)
AL Amyloidosis and Patient Reported Quality of Life (2015) (0)
Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study (2014) (0)
Prognostic Role of IL-6 in POEMS Syndrome (2021) (0)
A Phase II Study of Alemtuzumab in the Treatment of Plasma Cell Disorders. (2006) (0)
Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents (2016) (0)
Blood mass spectrometry Detects Residual Disease Better than Standard Techniques in Immunoglobulin light chain amyloidosis (2019) (0)
Clinical outcomes in t(11;14) multiple myeloma. (2015) (0)
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis (2020) (0)
Experience with Autologous HSC Transplant in Therapy-Related MDS/AML Using Cells Harvested Prior to the Development of the Secondary Malignancy. (2007) (0)
Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients with Previous Diagnosis of Multiple Myeloma (MM). (2009) (0)
Abstract 2582: P2X7 receptor is functional in myeloma cell lines and myeloma patient cells and can be modulated by P2X7 receptor antagonists: Implications for myeloma therapy (2011) (0)
Bortezomib Versus Non-Bortezomib Based Initial Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John Anthony Lust?

John Anthony Lust is affiliated with the following schools:

Illinois State University